摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2',3'-二氟苯基-4'-甲基苯乙酮 | 261763-30-8

中文名称
2',3'-二氟苯基-4'-甲基苯乙酮
中文别名
2',3'-二氟-4'-甲基苯乙酮
英文名称
1-(2,3-difluoro-4-methylphenyl)ethanone
英文别名
2',3'-Difluoro-4'-methylacetophenone
2',3'-二氟苯基-4'-甲基苯乙酮化学式
CAS
261763-30-8
化学式
C9H8F2O
mdl
——
分子量
170.159
InChiKey
PIYDLEQMYRPHPO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    221.7±35.0 °C(Predicted)
  • 密度:
    1.168±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    描述:
    2',3'-二氟苯基-4'-甲基苯乙酮 在 phenyltrimethylammonium tribromide 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 生成 2-bromo-1-(2,3-difluoro-4-methylphenyl)ethanone
    参考文献:
    名称:
    [EN] SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES
    [FR] DÉRIVÉS DE DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE SUBSTITUÉS
    摘要:
    这项发明涉及替代二氢吡唑吡嗪羧酰胺衍生物,以及它们的制备方法,还涉及它们用于制备治疗和/或预防疾病的药物,特别是心血管疾病,优选为血栓性或血栓栓塞性疾病,糖尿病,以及泌尿生殖和眼科疾病。
    公开号:
    WO2019219517A1
点击查看最新优质反应信息

文献信息

  • 8-Substituted isoquinoline derivative and the use thereof
    申请人:Kaneko Shunsuke
    公开号:US20100261701A1
    公开(公告)日:2010-10-14
    The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
    本发明涉及一种由以下式(1)表示的化合物: 其中D1,A1,D2,R1,D3和R2分别具有与本说明书中定义的相同含义或其盐。由式(1)表示的化合物或其盐具有IKKβ抑制活性等,对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
  • 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF
    申请人:Asahi Kasei Pharma Corporation
    公开号:EP2366699A1
    公开(公告)日:2011-09-21
    The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
    本发明涉及下式(1)所代表的化合物: 其中 D1、A1、D2、R1、D3 和 R2 各具有与本说明书中定义相同的含义或其盐。式(1)代表的化合物或其盐具有 IKKβ 抑制活性等,可用于预防和/或治疗 IKKβ 相关疾病或症状等。
  • NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP3321256A1
    公开(公告)日:2018-05-16
    Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    本发明提供了一种新型低分子量化合物,它能抑制诱导型 MMP(尤其是 MMP-9)的产生,而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式(I)代表的化合物: 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用,可作为预防和/或治疗自身免疫性疾病(如类风湿性关节炎等)、炎症性肠病(溃疡性结肠炎、克罗恩病)或骨关节炎的药物。
  • Imide derivatives and use thereof as medicine
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US10407408B2
    公开(公告)日:2019-09-10
    Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.
    本发明提供了一种新型低分子量化合物,它能抑制诱导型 MMP(尤其是 MMP-9)的产生,而不是抑制止血型 MMP-2 的产生。本发明涉及一种由下式(I)代表的化合物: 其中各符号如说明书所述。该化合物具有选择性抑制 MMP-9 生成的作用,可作为预防和/或治疗类风湿性关节炎等自身免疫性疾病、炎症性肠病(溃疡性结肠炎、克罗恩病)或骨关节炎的药物。
  • 10.1021/acs.orglett.4c01067
    作者:Liang, Min、Liu, Chuangchuang、Ju, Wenjie、Han, Shuxiong、Zhang, Jingyu、Zhao, Yingsheng
    DOI:10.1021/acs.orglett.4c01067
    日期:——
    Ortho-selective C–H borylation of aromatic ketones has not been extensively explored. Herein, we report the iridium-catalyzed ortho-selective C–H borylation of aromatic ketones using in situ-formed imine as the ligand. Good compatibility is observed for various substituted acetophenones and other aromatic ketones, and corresponding products are obtained with medium to excellent yields.
    芳香酮的邻位选择性C-H 硼基化尚未得到广泛探索。在此,我们报道了使用原位形成的亚胺作为配体,铱催化芳香酮的邻位选择性C-H硼化反应。与各种取代苯乙酮和其他芳香酮具有良好的相容性,并以中等至优异的收率得到相应的产物。
查看更多